RxDoctor Payments Data

Anna Imperato, MD

Internal Medicine · Manhasset, NYNPI 1104880780

Payments from drug & device makers

$422,329in general payments, 2019–2025

Across 2,190 payments — averaging $192.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$118K
  • Mallinckrodt Hospital Products Inc.$75K
  • Amgen$48K
  • Bristol Myers Squibb$47K
  • Novartis$42K
  • Kiniksa Pharmaceuticals International, PLC$22K
  • plus $69K from 43 others

What the payments were for

  • Consulting fees$31,8728%
  • Speaking & faculty fees$296,87970%
  • Travel & lodging$51,01012%
  • Food & beverage$41,00210%
  • Education$1,5660%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$422,329 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$2,421,548
Medicare patients
807
Services billed
133,780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast106$697,684
ArcalystRilonacept18$475,084
TremfyaGuselkumab28$431,617
Taltz AutoinjectorIxekizumab19$372,406
Cosentyx Sensoready (2 Pens)Secukinumab39$363,588
Gamunex-CImmune Globul G/Gly/Iga Avg 4624$355,840
RinvoqUpadacitinib14$223,721
TymlosAbaloparatide52$210,271
Cosentyx Unoready PenSecukinumab11$206,375
Orencia ClickjectAbatacept11$100,396
ActemraTocilizumab17$66,957
Sulfasalazine DrSulfasalazine219$12,901
Colchicine103$9,164
Mesalamine21$8,637
Hydroxychloroquine Sulfate187$6,882

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$48,387$697,684106 claims
Kiniksa Pharmaceuticals International, PLCArcalyst$22,114$475,08418 claims
Johnson & JohnsonTremfya$21,455$431,61728 claims
Grifols USA, LLCGamunex-C$108$355,84024 claims
AbbVieRinvoq$7,757$223,72114 claims
Radius Health, Inc.Tymlos$1,160$210,27152 claims
Genentech, Inc.Actemra$40$66,95717 claims
Scilex Pharmaceuticals Inc.Colchicine$104$9,164103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Manhasset

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →